PMC:7441788 / 134-1685
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 248-257 | Body_part | denotes | malarials | http://purl.org/sig/ont/fma/fma46831 |
T2 | 430-438 | Body_part | denotes | endosome | http://purl.org/sig/ont/fma/fma67180 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T3 | 9-33 | Disease | denotes | Coronavirus Disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 35-43 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 56-103 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 56-89 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
T7 | 105-113 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 196-204 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 344-352 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T10 | 609-617 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T11 | 722-730 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T12 | 893-901 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T13 | 1146-1154 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T14 | 1241-1249 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T15 | 1356-1364 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T16 | 1439-1447 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 476-484 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T2 | 522-530 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T3 | 585-586 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T4 | 619-620 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T5 | 842-843 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 1082-1083 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T5 | 216-221 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T6 | 259-270 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T7 | 272-274 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T8 | 280-298 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T9 | 354-356 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T10 | 679-681 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T11 | 806-808 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T12 | 844-853 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T13 | 1045-1047 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T14 | 1084-1093 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T15 | 1218-1220 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T16 | 1332-1334 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T17 | 1414-1425 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
T18 | 1429-1431 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T1 | 228-241 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | investigation | http://purl.bioontology.org/ontology/MEDDRA/10062026 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T3 | 259-270 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T4 | 272-274 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T5 | 280-298 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T6 | 354-356 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T7 | 679-681 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T8 | 806-808 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T9 | 844-853 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T10 | 1045-1047 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T11 | 1084-1093 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T12 | 1218-1220 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T13 | 1332-1334 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T14 | 1429-1431 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T2 | 9-33 | Species | denotes | Coronavirus Disease 2019 | NCBItxid:2697049 |
T3 | 35-43 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T4 | 56-103 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | NCBItxid:2697049 |
T5 | 105-115 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T6 | 196-204 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T7 | 344-352 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T8 | 609-617 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T9 | 722-732 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T10 | 893-901 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T11 | 1146-1154 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T12 | 1241-1249 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T13 | 1356-1364 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T14 | 1439-1447 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T6 | 0-8 | Sentence | denotes | ABSTRACT |
T7 | 9-141 | Sentence | denotes | Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. |
T8 | 142-205 | Sentence | denotes | Antiviral therapy is the most important treatment for COVID-19. |
T9 | 206-353 | Sentence | denotes | Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. |
T10 | 354-531 | Sentence | denotes | CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. |
T11 | 532-618 | Sentence | denotes | These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. |
T12 | 619-768 | Sentence | denotes | A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. |
T13 | 769-994 | Sentence | denotes | Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. |
T14 | 995-1155 | Sentence | denotes | However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. |
T15 | 1156-1259 | Sentence | denotes | Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. |
T16 | 1260-1551 | Sentence | denotes | Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
40 | 806-812 | Gene | denotes | CQ/HCQ | |
41 | 56-103 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
42 | 105-115 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
43 | 407-420 | Species | denotes | coronaviruses | Tax:11118 |
44 | 697-710 | Species | denotes | coronaviruses | Tax:11118 |
45 | 722-732 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
46 | 1132-1140 | Species | denotes | patients | Tax:9606 |
47 | 1250-1258 | Species | denotes | patients | Tax:9606 |
48 | 259-270 | Chemical | denotes | chloroquine | MESH:D002738 |
49 | 272-274 | Chemical | denotes | CQ | MESH:D002738 |
50 | 280-298 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
51 | 300-303 | Chemical | denotes | HCQ | MESH:D006886 |
52 | 679-681 | Chemical | denotes | CQ | MESH:D002738 |
53 | 682-685 | Chemical | denotes | HCQ | MESH:D006886 |
54 | 844-853 | Chemical | denotes | macrolide | MESH:D018942 |
55 | 1045-1051 | Chemical | denotes | CQ/HCQ | |
56 | 1084-1093 | Chemical | denotes | macrolide | MESH:D018942 |
57 | 1218-1220 | Chemical | denotes | CQ | MESH:D002738 |
58 | 1221-1224 | Chemical | denotes | HCQ | MESH:D006886 |
59 | 1332-1334 | Chemical | denotes | CQ | MESH:D002738 |
60 | 1335-1338 | Chemical | denotes | HCQ | MESH:D006886 |
61 | 1429-1431 | Chemical | denotes | CQ | MESH:D002738 |
62 | 1432-1435 | Chemical | denotes | HCQ | MESH:D006886 |
63 | 9-33 | Disease | denotes | Coronavirus Disease 2019 | MESH:C000657245 |
64 | 35-43 | Disease | denotes | COVID-19 | MESH:C000657245 |
65 | 196-204 | Disease | denotes | COVID-19 | MESH:C000657245 |
66 | 344-352 | Disease | denotes | COVID-19 | MESH:C000657245 |
67 | 609-617 | Disease | denotes | COVID-19 | MESH:C000657245 |
68 | 893-901 | Disease | denotes | COVID-19 | MESH:C000657245 |
69 | 933-946 | Disease | denotes | delay disease | MESH:D003141 |
70 | 1146-1154 | Disease | denotes | COVID-19 | MESH:C000657245 |
71 | 1241-1249 | Disease | denotes | COVID-19 | MESH:C000657245 |
72 | 1356-1364 | Disease | denotes | COVID-19 | MESH:C000657245 |
73 | 1439-1447 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 21-28 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | Disease |
T2 | 142-151 | http://purl.obolibrary.org/obo/IDO_0000559 | denotes | Antiviral |
T3 | 881-889 | http://purl.obolibrary.org/obo/OGMS_0000020 | denotes | symptoms |
T4 | 939-946 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 248-257 | Body_part | denotes | malarials | http://purl.org/sig/ont/fma/fma46831 |
T2 | 430-438 | Body_part | denotes | endosome | http://purl.org/sig/ont/fma/fma67180 |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 439-452 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T2 | 476-491 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 9-33 | Disease | denotes | Coronavirus Disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 35-43 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 56-103 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 105-115 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 196-204 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 344-352 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T8 | 609-617 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 722-732 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T10 | 893-901 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T11 | 1146-1154 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T12 | 1241-1249 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T13 | 1356-1364 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T14 | 1439-1447 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sample-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 1183-1204 | Phenotype | denotes | prolonged QT interval | http://purl.obolibrary.org/obo/HP_0001657 |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 439-452 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T2 | 476-491 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 439-452 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T2 | 476-491 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
40 | 806-812 | Gene | denotes | CQ/HCQ | |
41 | 56-103 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
42 | 105-115 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
43 | 407-420 | Species | denotes | coronaviruses | Tax:11118 |
44 | 697-710 | Species | denotes | coronaviruses | Tax:11118 |
45 | 722-732 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
46 | 1132-1140 | Species | denotes | patients | Tax:9606 |
47 | 1250-1258 | Species | denotes | patients | Tax:9606 |
48 | 259-270 | Chemical | denotes | chloroquine | MESH:D002738 |
49 | 272-274 | Chemical | denotes | CQ | MESH:D002738 |
50 | 280-298 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
51 | 300-303 | Chemical | denotes | HCQ | MESH:D006886 |
52 | 679-681 | Chemical | denotes | CQ | MESH:D002738 |
53 | 682-685 | Chemical | denotes | HCQ | MESH:D006886 |
54 | 844-853 | Chemical | denotes | macrolide | MESH:D018942 |
55 | 1045-1051 | Chemical | denotes | CQ/HCQ | |
56 | 1084-1093 | Chemical | denotes | macrolide | MESH:D018942 |
57 | 1218-1220 | Chemical | denotes | CQ | MESH:D002738 |
58 | 1221-1224 | Chemical | denotes | HCQ | MESH:D006886 |
59 | 1332-1334 | Chemical | denotes | CQ | MESH:D002738 |
60 | 1335-1338 | Chemical | denotes | HCQ | MESH:D006886 |
61 | 1429-1431 | Chemical | denotes | CQ | MESH:D002738 |
62 | 1432-1435 | Chemical | denotes | HCQ | MESH:D006886 |
63 | 9-33 | Disease | denotes | Coronavirus Disease 2019 | MESH:C000657245 |
64 | 35-43 | Disease | denotes | COVID-19 | MESH:C000657245 |
65 | 196-204 | Disease | denotes | COVID-19 | MESH:C000657245 |
66 | 344-352 | Disease | denotes | COVID-19 | MESH:C000657245 |
67 | 609-617 | Disease | denotes | COVID-19 | MESH:C000657245 |
68 | 893-901 | Disease | denotes | COVID-19 | MESH:C000657245 |
69 | 933-946 | Disease | denotes | delay disease | MESH:D003141 |
70 | 1146-1154 | Disease | denotes | COVID-19 | MESH:C000657245 |
71 | 1241-1249 | Disease | denotes | COVID-19 | MESH:C000657245 |
72 | 1356-1364 | Disease | denotes | COVID-19 | MESH:C000657245 |
73 | 1439-1447 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T6 | 0-8 | Sentence | denotes | ABSTRACT |
T7 | 9-141 | Sentence | denotes | Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. |
T8 | 142-205 | Sentence | denotes | Antiviral therapy is the most important treatment for COVID-19. |
T9 | 206-353 | Sentence | denotes | Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. |
T10 | 354-531 | Sentence | denotes | CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. |
T11 | 532-618 | Sentence | denotes | These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. |
T12 | 619-768 | Sentence | denotes | A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. |
T13 | 769-994 | Sentence | denotes | Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. |
T14 | 995-1155 | Sentence | denotes | However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. |
T15 | 1156-1259 | Sentence | denotes | Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. |
T16 | 1260-1551 | Sentence | denotes | Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 1183-1204 | Phenotype | denotes | prolonged QT interval | http://purl.obolibrary.org/obo/HP_0001657 |